Individuals with HIV at higher risk for heart disease

January 25, 2018, American Physiological Society
Credit: CC0 Public Domain

A review of more than 80 studies reveals that changes in the immune cells of people with human immunodeficiency virus (HIV) infection may increase their risk of cardiovascular disease (CVD). The review is published in the journal Physiology.

Combination (cART) consists of a "cocktail" of several drugs that work together to reduce the amount of detectable virus (viral load) in the bloodstream. Since the development of this combination treatment approach more than 20 years ago, antiretroviral therapy has helped millions of people with HIV escape a once-certain death sentence. However, even with very low viral loads, approximately 20 percent of HIV-positive patients die of heart disease, and studies have shown that treatment with cART is associated with a higher risk of heart attack. Paradoxically, the medications in cART that help people with HIV live longer also have many harmful effects on the cardiovascular system. These drugs have been found to increase (a type of cell damage), impair the body's ability to digest fat and damage blood vessels. But HIV-positive patients who do not take cART are also at risk for CVD, because HIV itself can lead to heart problems.

A team of researchers from Stellenbosch University in South Africa report that persistent immune activation may contribute to the increased risk of CVD seen in patients with HIV. Immune activation is a normal and essential function that occurs when the body responds to infection. However, the constant presence of HIV in the body, even at very low levels, causes the immune system to remain activated continuously, leading to long-term inflammation and depletion of T cells that help the body fight infection. These factors, together with damage to the lining of the blood vessels, can lead to permanent changes in the .

Increased immune activation and oxidative stress "contribute to the pathogenesis of complications such as CVD, renal disease and cancer," the research team wrote. "Persistent immune activation is a driver of CVD in HIV-infected individuals (treated and untreated)." Future study about the metabolic changes in the immune system and the effect immune function may help reduce the risk of heart disease in people with HIV, added the researchers.

"HIV and : role of immunometabolic perturbations" is published in Physiology.

Explore further: Early antiretroviral therapy reduces gut inflammation in HIV+ individuals

More information: Eman Teer et al. HIV and Cardiovascular Disease: Role of Immunometabolic Perturbations, Physiology (2017). DOI: 10.1152/physiol.00028.2017

Related Stories

Early antiretroviral therapy reduces gut inflammation in HIV+ individuals

July 7, 2016
Combination antiretroviral therapy (cART) suppresses HIV replication and significantly slows the progression of disease, enabling HIV+ individuals to effectively manage infection for long periods. One of the manifestations ...

Unique pattern of brain inflammation may explain neurocognitive impairment in HIV patients on antiretroviral drugs

December 8, 2017
Although combination antiretroviral therapy (cART) has improved survival of patients infected with HIV and has reduced the incidence of severe neurologic complications, almost half of cART-treated HIV patients experience ...

Interfering with interferon boosts antiretroviral efficacy in HIV-infected mice

December 12, 2016
Although combined anti-retroviral therapy (cART) can help HIV-1-positive patients effectively manage their infection, some individuals experience ongoing activation of the immune system that can exacerbate disease progression. ...

Early-life trauma may increase heart disease risk in adults

December 8, 2017
Stress in early life may change the immune response in the kidneys, increasing the risk of heart disease later in life, according to a new study. The paper, published ahead of print in the American Journal of Physiology—Renal ...

Antiretroviral therapy may not be enough to reduce HIV-associated arterial inflammation

May 25, 2016
Initiating antiretroviral therapy (ART) soon after diagnosis of an HIV infection did not prevent the progression of significant arterial inflammation in a small group of previously untreated patients. The findings from a ...

Pretreatment HIV, immune activation levels determine their persistence during treatment

April 20, 2017
A study led by a Massachusetts General Hospital (MGH) investigator may have answered a major debate in HIV research - whether the tiny amounts of HIV that persist in patients receiving long-term antiretroviral treatment (ART) ...

Recommended for you

HIV vaccine protects non-human primates from infection

December 14, 2018
For more than 20 years, scientists at Scripps Research have chipped away at the challenges of designing an HIV vaccine. Now new research, published in Immunity, shows that their experimental vaccine strategy works in non-human ...

Roadmap reveals shortcut to recreate key HIV antibody for vaccines

December 11, 2018
HIV evades the body's immune defenses through a multitude of mutations, and antibodies produced by the host's immune system to fight HIV also follow convoluted evolutionary pathways that have been challenging to track.

Eliminating the latent reservoir of HIV

December 7, 2018
A new study suggests that a genetic switch that causes latent HIV inside cells to begin to replicate can be manipulated to completely eradicate the virus from the human body. Cells harboring latent HIV are "invisible" to ...

New research highlights why HIV-infected patients suffer higher rates of cancer

December 5, 2018
AIDS patients suffer higher rates of cancer because they have fewer T-cells in their bodies to fight disease. But new research examines why HIV-infected patients have higher rates of cancer—among the leading causes of death ...

Focus on resistance to HIV offers insight into how to fight the virus

November 30, 2018
Of the 40 million people around the world infected with HIV, less than one per cent have immune systems strong enough to suppress the virus for extended periods of time. These special immune systems are known as "elite controllers." ...

Patients with rare natural ability to suppress HIV shed light on potential functional cure

November 27, 2018
Researchers at Johns Hopkins have identified two patients with HIV whose immune cells behave differently than others with the virus and actually appear to help control viral load even years after infection. Moreover, both ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.